While Kaseb et al. showed that CD8+ T cell infiltration in HCC can be a predictive biomarker for ICB response (78), another recent study revealed that CD8+ T cell infiltration was not enough for predicting the therapeutic efficacy of ICB in HCC (79). This evidence concerns the gene CD8A and hepatocellular carcinoma.